Proof — Case Study

Vera Therapeutics
Clinical data, communicated.

Science Story™Science Studio™

Biotech-grade science, made accessible to investors, clinicians, and KOLs.

The Work
The MOA Video
The Story

As a clinical-stage biotech, Vera Therapeutics needed to communicate complex advancements — the atacicept mechanism of action and new, positive ORIGIN trial results in IgA nephropathy — to investors, clinicians, and key opinion leaders at once.

We produced a series of educational videos highlighting the MOA and showcasing the latest trial data: visually engaging tools that build understanding and confidence with clinical and non-clinical audiences alike, supporting investment discussions and medical community engagement.

  • MOA video series
  • Clinical data visualization
  • Investor + KOL education
Results
Phase 3 science
ORIGIN trial data, visualized
One asset, three audiences
Investors, clinicians, KOLs

More work

Case StudyBausch + Lomb83 studies. 35 new claims. Three weeks.View →Case StudyCheers Health — MOAScience, share-worthy.View →Case StudyCheers HealthThree weeks, not six months.View →Case StudyDesigns for HealthNot all vitamin D is equal.View →Case StudyEmerson Logistics1 order. 1 truck. 1 payment.View →Case StudyFlonaseOne dose. Six allergens.View →Case StudyHealthCareAislePrivate label, public proof.View →Case StudyiVIZIAWe see a better way.View →Case StudyLotriminAthlete's foot loves a comeback.View →Case StudyMetrum Research GroupComplexity, distilled.View →Case StudyNexium 24HRBold claims win.View →Case StudyQunol10x better absorption.View →

Want results like these?

Every one of them started with the science.

Start a Project